| Replacement Information | |
|---|---|
| Replacement Information | 05-1424 is a recommended replacement for MAB2152 |
Special Offers
100% Performance Guaranteed
Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H, M, R | WB, IHC, ICC, IP, FC, ELISA | M | Purified | Monoclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | 05-1424 |
| Replaces | MAB2152 |
| Description | Anti-Endoglin Antibody, clone P3D1 |
| Alternate Names |
|
| Background Information | Endoglin is a homodimeric integral membrane glycoprotein comprised of 95 kDa subunit. Endoglin is a component of the TGF-B receptor system that functions as an ancillary receptor influencing binding of the Transforming Growth Factor beta (TGF-β) family ligands to signaling receptors. Endoglin binds TGF-B1 and TGF-B3 with high affinity but does not bind TGF-B2. Endoglin is expressed by vascular endothelial cells and syncytiotrophoblasts of placenta and is weakly expressed by stromalfibroblasts. It is also expressed by U937 cells and activated macrophages. Endoglin expression is up regulated on activated endothelium in tissues undergoing angiogenesis, such as in tumors, or in cases of wound healing or dermal inflammation. |
| Product Information | |
|---|---|
| Format | Purified |
| Control |
|
| Presentation | Purified mouse monoclonal IgG2a in 0.02M phosphate buffer, 0.25M sodium chloride, 0.1% sodium azide, pH 7.6 |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Anti-Endoglin Antibody, clone P3D1 is an antibody against Endoglin for use in WB, IH, IC, IP, FC, ELISA. |
| Key Applications |
|
| Application Notes | Immunohistochemistry: For use on acetone or paraformaldehyde fixed tissue. ELISA: A previous lot of this antibody was used in ELISA. Immunoprecipitation: A previous lot of this antibody was used in IP. Immunocytochemistry: A previous lot of this antibody was used in IC. Flow Cytometry: A previous lot of this antibody was used in FC. Optimal working dilutions must be determined by the end user. |
| Biological Information | |
|---|---|
| Immunogen | Human resting umbilical vein endothelial cells. |
| Clone | P3D1 |
| Concentration | Please refer to the Certificate of Analysis for the lot-specific concentration. |
| Host | Mouse |
| Specificity | Reacts with human endoglin. |
| Isotype | IgG2a |
| Species Reactivity |
|
| Species Reactivity Note | Human and mouse. Expected to react with rat based on sequence homology. |
| Antibody Type | Monoclonal Antibody |
| Entrez Gene Number |
|
| Entrez Gene Summary | Endoglin is a homodimeric transmembrane glycoprotein highly expressed by endothelial cells. It is a component of the transforming growth factor beta receptor complex as it binds TGFB1 and TGFB3 with high affinity. Mutations in the endoglin gene produce hereditary hemorrhagic telangiectasia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
| Gene Symbol |
|
| Purification Method | Purified |
| UniProt Number |
|
| UniProt Summary | FUNCTION: SwissProt: P17813 # Major glycoprotein of vascular endothelium. May play a critical role in the binding of endothelial cells to integrins and/or other RGD receptors. SIZE: 658 amino acids; 70578 Da SUBUNIT: Homodimer that forms an heteromeric complex with the signaling receptors for transforming growth factor-beta: TGF-beta receptors I and/or II. It is able to bind TGF-beta 1, and 3 efficiently and TGF-beta 2 less efficiently. SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein. TISSUE SPECIFICITY: Endoglin is restricted to endothelial cells in all tissues except bone marrow. DISEASE: SwissProt: P17813 # Defects in ENG are the cause of hereditary hemorrhagic telangiectasia type 1 (HHT1) [MIM:187300, 108010]; also known as Osler-Rendu-Weber syndrome 1 (ORW1). HHT1 is an autosomal dominant multisystemic vascular dysplasia, characterized by recurrent epistaxis, muco-cutaneous telangiectases, gastro-intestinal hemorrhage, and pulmonary (PAVM), cerebral (CAVM) and hepatic arteriovenous malformations; all secondary manifestations of the underlying vascular dysplasia. Although the first symptom of HHT1 in children is generally nose bleed, there is an important clinical heterogeneity. |
| Molecular Weight | ~71 kDa |
| Product Usage Statements | |
|---|---|
| Quality Assurance | Routinely evaluated by Western Blot on Jurkat lysates. Western Blot Analysis: 1:500 dilution of this lot detected ENDOGLIN on 10 μg of Jurkat lysates. |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Stable at 2-8°C for up to 1 year from date of receipt. |
| Packaging Information | |
|---|---|
| Material Size | 100 µg |